Cancer research communications
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid Tumors.
Jong Chul Park, David Berz, Manish R Sharma, Jyoti Malhotra, Anthony W Tolcher, Ralph J Hauke, Justin A Call, John T Hamm, Rachel E Sanborn, Naomi B Haas, Frank Tsai, Doug R Adkins, David R Camidge, Alexander I Spira, Lane Senne
Published: 202610.1158/2767-9764.CRC-25-0577
Abstract
PURPOSE: INBRX-105, a tetravalent, PD-L1-targeted TNFRSF9 (4-1BB) agonist, demonstrated preclinical antitumor activity. This first-in-human study evaluated INBRX-105 in solid tumors. PATIENTS AND METHODS: This open-label, 4-part, phase 1 study evalua…
Preview only. Read the full abstract at the source